

# WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Monday, November 21, 2005

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND</i>		
<input type="checkbox"/>	L1	cenp-e	135

END OF SEARCH HISTORY



A service of the National Library of Medicine  
and the National Institutes of Health

www.pubmed.gov

My NCBI  
[Sign In] [Reg]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bc

Search PubMed for alzhaimers clinical diagnosis diagnostic protein rev Preview Go C

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Search

Most Recent Queries

Time Result

#6 Search alzhaimers clinical diagnosis diagnostic protein review	10:14:03	148
#5 Search alzhaimers clinical diagnosis diagnostic proteinreview	10:00:32	3002
#4 Search alzhaimers clinical diagnosis diagnostic review	10:00:16	685
#3 Search alzhaimers diagnosis diagnostic review	09:59:59	1474
#2 Search alzhaimers diagnosis review	09:58:58	3714
#1 Search alzhaimers diagnostic review	09:58:40	1537

Clear History

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 15 2005 04:49:13



Search  for

Limits Preview/Index History Clipboard Details

Display  Show  Sort by  Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Arch Neurol. 1999 Mar;56(3):281-3.

Related Articles, Links



## Biomarkers of Alzheimer disease.

Growdon JH.

Department of Neurology, Massachusetts General Hospital, Boston 02114, USA.

A definitive diagnosis of Alzheimer disease (AD) depends on finding widespread neurofibrillary tangles and plentiful neuritic plaques in the brain of an individual with a clinical diagnosis of progressive dementia. Using contemporary diagnostic criteria, the antemortem diagnosis of probable AD in centers specialized for AD is confirmed 80% to 90% of the time. There is the suspicion, but no firm data, that diagnostic accuracy is much lower outside of practices dedicated to patients with dementia. Furthermore, the diagnostic workup is expensive. In most settings, the evaluation generally includes a careful medical history and physical examination; neurologic examination (and psychiatric consultation as indicated); laboratory blood studies to exclude underlying metabolic and medical illnesses that masquerade as AD; a mental status assessment and formal cognitive tests; and a computed tomographic scan or magnetic resonance imaging of the brain. Because these procedures are time-consuming and costly, there is a need to identify biological tests that can circumvent aspects of this workup and point the physician to the correct diagnosis. It would be highly desirable to measure a substance or substances in blood or urine samples or cerebrospinal fluid (CSF) that would lead to a positive diagnosis of AD without the need for specialized dementia clinics and the expense and time of standard diagnostic evaluations. In response to this need, the Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging convened a working group in 1997 to examine the status of various antemortem markers for AD. The consensus statement of this group, entitled "Molecular and Biochemical Markers of AD," was published in 1998. The consensus statement first defined the characteristics of an ideal biomarker, and then outlined the steps required for a proposed biomarker to achieve acceptance by the medical community. Finally, the statement reviewed the current state of all proposed biological markers. The workshop





participants observed that none of the current biomarkers had yet achieved universal acceptance and concluded none fully met the consensus criteria for an ideal marker. Nonetheless, several tests were identified as good markers for familial AD, and several other tests showed promise as a diagnostic aid for sporadic AD. The purpose of this review is to put these recommendations into a practical context. What does the consensus statement tell the practicing clinician? How do the opinions in the consensus statement affect clinical practice in diagnosing and treating patients with dementia?

Publication Types:

- [Review](#)
- [Review, Tutorial](#)

PMID: 10190817 [PubMed - indexed for MEDLINE]

---

Display [Abstract](#)  Show [20](#)  Sort by  Send to 

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
Department of Health & Human Services  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 15 2005 04:49:13



A service of the National Library of Medicine  
and the National Institutes of Health

www.pubmed.gov

My NCBI  
[Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for [ ] Go Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show 20 Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Ann Clin Biochem. 2000 Sep;37 ( Pt 5):593-607.

Related Articles, Links

## Genetic and biochemical markers for Alzheimer's disease: recent developments.

Mulder C, Scheltens P, Visser JJ, van Kamp GJ, Schutgens RB.

Department of Clinical Chemistry, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.

Publication Types:

- Review
- Review, Tutorial

PMID: 11026514 [PubMed - indexed for MEDLINE]

Display Abstract Show 20 Sort by Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Nov 15 2005 04:49:13